




UNITED STATES PATENT AND TRADEMARK OFFICE

227011
 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/580,662	FIRST NAMED APPLICANT Patrick Gerard Johnston	ATTY. DOCKET NO. 36290-0416-00-US
---	--	--------------------------------------

23973

DRINKER BIDDLE & REATH
 ATTN: INTELLECTUAL PROPERTY GROUP
 ONE LOGAN SQUARE
 18TH AND CHERRY STREETS
 PHILADELPHIA, PA 19103-6996



INTERNATIONAL APPLICATION NO.

PCT/GB04/05008

I.A. FILING DATE

11/26/2004

PRIORITY DATE

11/26/2003

CONFIRMATION NO. 5029

371 FORMALITIES LETTER



OC000000022639618


Date Mailed: 02/26/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.



For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/580,662	PCT/GB04/05008	36290-0416-00-US

FORM PCT/DO/EO/922 (371 Formalities Notice)

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/580,662
Source: IFWP
Date Processed by STIC: 2/1/07

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 4.4.0 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chknote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/10/06

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 10/580,662
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1 _____ Wrapped Nucleics _____ Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 _____ Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 _____ Misaligned Amino _____ Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 _____ Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 _____ Variable Length	Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 _____ PatentIn 2.0 _____ "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 _____ Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence: (Z) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (ii) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
8 _____ Skipped Sequences (NEW RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
9 _____ Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
10 _____ Invalid <213> _____ Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence. (see item 11 below)	
11 _____ Use of <220>	Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown". Please explain source of genetic material in <220> to <223> section or use "chemically synthesized" as explanation. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32), also Sec. 1.823 of Sequence Rules	
12 _____ PatentIn 2.0 _____ "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 _____ Misuse of n/Xaa	"n" can only represent a single nucleotide. "Xaa" can only represent a single amino acid	



IFWP

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/580,662

DATE: 02/01/2007

TIME: 11:44:50

Input Set : A:\seqlisting.txt

Output Set: N:\CRF4\02012007\J580662.raw

3 <110> APPLICANT: Fusion Antibodies Limited
4 Johnston, Patrick Gerard
5 Longley, Daniel
7 <120> TITLE OF INVENTION: Combination Therapy
9 <130> FILE REFERENCE: 36290-0416-00-US
C--> 11 <140> CURRENT APPLICATION NUMBER: US/10/580,662
C--> 12 <141> CURRENT FILING DATE: 2006-05-26
14 <150> PRIOR APPLICATION NUMBER: GB0327493.3
15 <151> PRIOR FILING DATE: 2003-11-26
17 <160> NUMBER OF SEQ ID NOS: 4
19 <170> SOFTWARE: PatentIn version 3.3
21 <210> SEQ ID NO: 1
22 <211> LENGTH: 18
23 <212> TYPE: DNA
24 <213> ORGANISM: Artificial
26 <220> FEATURE:
27 <223> OTHER INFORMATION: Pas (forward)
29 <400> SEQUENCE: 1
30 aaaggctttg ttcgaaag
33 <210> SEQ ID NO: 2
34 <211> LENGTH: 20
35 <212> TYPE: DNA
36 <213> ORGANISM: Artificial
38 <220> FEATURE:
39 <223> OTHER INFORMATION: Pas (reverse)
41 <400> SEQUENCE: 2
42 cactctagac caagctttgg
45 <210> SEQ ID NO: 3
46 <211> LENGTH: 19
47 <212> TYPE: DNA
48 <213> ORGANISM: Artificial
50 <220> FEATURE:
51 <223> OTHER INFORMATION: 18S (forward)
53 <400> SEQUENCE: 3
54 cattegtatt ggcacgcta
57 <210> SEQ ID NO: 4
58 <211> LENGTH: 19
59 <212> TYPE: DNA
60 <213> ORGANISM: Artificial
62 <220> FEATURE:
63 <223> OTHER INFORMATION: 18S (reverse)
65 <400> SEQUENCE: 4
66 cgacggatc tgategtct

Does Not Comply
Corrected Diskette Needed

*please explain
further - give more
information regarding
this
response*
*(since the application's
specification is not
described here, please
give source of genetic material
(see item 11
on Ena summary sheet))*

19

19

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/580,662

DATE: 02/01/2007
TIME: 11:44:51

Input Set : A:\seqlisting.txt
Output Set: N:\CRF4\02012007\J580662.raw

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete,
per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#: 1, 2, 3, 4

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/580,662

DATE: 02/01/2007

TIME: 11:44:51

Input Set : A:\seqlisting.txt

Output Set: M:\CRF4\02012007\J580662.raw

L:11 M:270 C: Current Application Number differs, Replaced Current Application Number
L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date